Want to see ELDN full AI Analyst Report?
Top Page
Eledon Pharmaceuticals
(NASDAQ:ELDN)
Select Model
Select Model
Rating:49Neutral
Price Target:
$3.50
▼(-2.23% Downside)
Action:Reiterated
Date:06/23/26
The score is held down primarily by persistent pre-revenue losses and substantial cash burn that likely necessitate future financing, reinforced by the authorized share increase and dilution risk. A low-leverage balance sheet and constructive price trend provide partial offsets, but valuation metrics remain challenged due to ongoing losses.
Positive Factors
Low Leverage Balance Sheet
Very low debt reduces insolvency risk and gives management financial flexibility to fund R&D and clinical programs without immediate refinancing pressure. This structural strength supports multi-stage clinical development timelines and strategic optionality over the next 2–6 months.
Negative Factors
Pre-Revenue Operations
As a clinical-stage biotech with no product revenue, the company must rely on external funding until commercialization or partnerships deliver revenue. This structural lack of revenue prolongs dependence on capital markets and increases execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage Balance Sheet
Very low debt reduces insolvency risk and gives management financial flexibility to fund R&D and clinical programs without immediate refinancing pressure. This structural strength supports multi-stage clinical development timelines and strategic optionality over the next 2–6 months.
Read all positive factors
Eledon Pharmaceuticals (ELDN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$284.05M
Dividend YieldN/A
Average Volume (3M)1.57M
Price to Earnings (P/E)―
Beta (1Y)1.47
Revenue GrowthN/A
EPS Growth-1.48%
CountryUS
Employees33
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.87
Shares Outstanding77,187,820
10 Day Avg. Volume888,396
30 Day Avg. Volume1,569,320
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.98
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.50Price Target Upside165.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.88
Revenue Forecast (FY)N/A
Eledon Pharmaceuticals Business Overview & Revenue Model
Company Description
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantat...
How the Company Makes Money
null...
Eledon Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -78.03M | -45.27M | -35.39M | -116.16M | -39.41M | -36.66M |
| Net Income | -78.15M | -45.62M | -36.18M | -116.54M | -87.97M | -34.51M |
Balance Sheet | ||||||
| Total Assets | 146.67M | 169.01M | 177.41M | 89.07M | 92.79M | 170.55M |
| Cash, Cash Equivalents and Short-Term Investments | 111.09M | 133.34M | 140.18M | 51.10M | 56.41M | 84.83M |
| Total Debt | 555.00K | 641.00K | 954.00K | 383.00K | 746.00K | 769.00K |
| Total Liabilities | 46.21M | 87.92M | 59.27M | 81.86M | 8.61M | 6.55M |
| Stockholders Equity | 100.46M | 81.08M | 118.14M | 7.21M | 84.18M | 164.00M |
Cash Flow | ||||||
| Free Cash Flow | -68.89M | -62.34M | -47.27M | -39.53M | -28.42M | -28.91M |
| Operating Cash Flow | -68.89M | -62.34M | -47.27M | -39.53M | -28.42M | -28.91M |
| Investing Cash Flow | 12.86M | 10.79M | -70.31M | -45.29M | 0.00 | 0.00 |
| Financing Cash Flow | 53.69M | 53.81M | 133.52M | 33.02M | 0.00 | -449.00K |
Eledon Pharmaceuticals Technical Analysis
Positive
3.58
Price Trends
3.71
Positive
3.60
Positive
2.91
Positive
Market Momentum
-0.05
Negative
53.80
Neutral
81.65
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELDN, the sentiment is Positive. The current price of 3.58 is below the 20-day moving average (MA) of 3.64, below the 50-day MA of 3.71, and above the 200-day MA of 2.91, indicating a bullish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 53.80 is Neutral, neither overbought nor oversold. The STOCH value of 81.65 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ELDN.
Eledon Pharmaceuticals Risk Analysis
Eledon Pharmaceuticals disclosed 38 risk factors in its most recent earnings report. Eledon Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Eledon Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $321.70M | -2.51 | -58.89% | ― | -52.64% | 26.97% | |
53 Neutral | $343.93M | 3.03 | -6.74% | ― | -100.00% | 95.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $286.94M | -1.51 | -33.22% | ― | 215.59% | 22.48% | |
49 Neutral | $284.05M | -4.31 | -96.80% | ― | ― | -1.48% | |
47 Neutral | $249.94M | -3.82 | -86.63% | ― | -23.73% | -44.36% | |
43 Neutral | $259.34M | -3.71 | -147.80% | ― | 1.97% | -25.03% |
* Healthcare Sector Average
ELDN
Eledon Pharmaceuticals
3.75
1.15
44.23%
MGNX
MacroGenics
3.92
2.26
136.14%
FATE
Fate Therapeutics
2.74
1.61
142.48%
PRQR
ProQR
1.92
-0.10
-4.95%
BCYC
Bicycle Therapeutics
4.12
-3.23
-43.95%
SABS
SAB Biotherapeutics
3.76
1.61
74.88%
Eledon Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Eledon Pharmaceuticals Expands Authorized Shares After Stockholder Vote
Positive
Jun 22, 2026
At its Annual Meeting of Stockholders held on June 18, 2026, Eledon Pharmaceuticals’ shareholders elected David-Alexandre C. Gros, M.D., Jan Hillson, M.D., and James Robinson as Class III directors to serve three-year terms ending in 2029, r...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.